Pharmacology
Rufinamide Reduces Seizures in Treatment-Resistant Lennox-Gastaut Epilepsy
By American Academy of Neurology
Apr 13, 2005, 00:21

Lennox-Gastaut Syndrome is a catastrophic form of childhood epilepsy that is often resistant to treatment with conventional anti-seizure medications.

In this trial, 138 patients with treatment-resistant LGS received either the novel drug rufinamide or placebo for 12 weeks. Rufinamide reduced monthly seizure frequency by 33 percent, compared to 12 percent for placebo, and was especially beneficial in patients with so-called tonic-atonic seizures.

Sleepiness and vomiting were important drug side effects. This study provides support for use of the drug in LGS patients whose symptoms are not well controlled by other medications.

All rights reserved by www.rxpgnews.com